Induction Chemotherapy Followed by Standard Therapy in Cervical Cancer With Aortic Lymph Node Spread

Cervical Cancer TNM Staging Regional Lymph Nodes (N) Clinical Trial

— ONCOCOL01  

Official title:

Phase III Study Comparing Neoadjuvant Chemotherapy With Carboplatin and Paclitaxel Followed by Standard Therapy, With Standard Therapy Alone in Women With Cervical Cancer and Para Aortic Positive Lymph Node.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03534713
• Other study ID #: RC31/17/0213
• Status: Recruiting
• Phase: Phase 3
• Start date: July 17, 2020
• Est. completion date: December 2026

Study information

• Verified date: September 2023
• Source: University Hospital, Toulouse
• Contact: Stéphanie MOTTON, MD
• Phone: +335 61 32 37 08
• Email: motton.stephanie[@]iuct-oncopole.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main objective of this study is to determine whether neoadjuvant chemotherapy with Carboplatin and paclitaxel plus standard cisplatin-based chemoradiation with extended fields improves overall survival rates compared to standard therapy alone in women with cervical cancer with paraaortic lymph node involvement.

Women in the experimental arm will receive neoadjuvant chemotherapy with carboplatin and paclitaxel every 21 days during 3 cycles followed by standard therapy with extended field external radiation therapy and concomitant chemotherapy. Women in the control arm will receive standard therapy with extended field external radiation therapy and concomitant chemotherapy.

310 patients will be recruited during 4.5 years, with 3 years of follow up period.

Description:

The survival outcome of patients with carcinoma of the cervix and positive paraaortic lymph node is poor and the potential benefit of neoadjuvant chemotherapy before extended field chemoradiotherapy has never been assessed.

Paraaortic nodal spread in cervical cancer is a blind spot in the management of cervical cancer. It is necessary to evaluate additional treatment.

While the presence of paraaortic nodal metastases often indicates occult systemic disease, the investigators continue to treat them as a loco-regional disease.

Using neoadjuvant chemotherapy, improvement of overall survival rates is expected in women with cervical cancer and para-aortic positive lymphadenopathy without increasing the incidence of further toxicity.

The propose is to determine whether neoadjuvant chemotherapy with Carboplatin and paclitaxel plus standard cisplatin-based chemoradiation with extended fields improves overall survival rates compared to standard therapy alone in women with cervical cancer with paraaortic lymph node involvement.

Secondary objectives will be to compare progression free survival, acute and long term toxicities, patterns of disease recurrence and patient quality of life between arms This is a phase III, multicenter, randomized, open label study, recruiting 310 patients during 4.5 years, with 3 years of follow up period.

Two groups will be compared : neoadjuvant chemotherapy with Carboplatin and paclitaxel plus standard cisplatin-based chemoradiation with extended fields, versus standard therapy alone.

Randomization will be stratified according to International federation of gynecology and obstetrics stages at diagnosis (IB1, IB2, IIA versus IIB-IVA), the size of positive para aortic lymphadenopathy and the number of node involved and will be balanced by blocks.

Women in the experimental arm will receive neoadjuvant chemotherapy with carboplatin and paclitaxel followed by standard therapy with extended field external radiation therapy and concomitant chemotherapy then intracavitary brachytherapy, alone or prior to surgery, depending on response to treatment according to the current guidelines.

Women in the control arm will receive standard therapy with extended field external radiation therapy and concomitant chemotherapy then brachytherapy, alone or prior to surgery, depending on response to treatment according to the current guidelines.

Follow up will be the same between arms. But in experimental arm, during treatment phase, a clinical examination and biological assessment will be performed before each cycle of neoadjuvant chemotherapy. Therefore, at the end of neoadjuvant treatment, just before standard treatment magnetic resonance imaging and positron emission tomography-computed tomography will be performed.

Then, all Participants will be followed every 4 months until 2 years after randomization and every 6 months during the third year according to current follow-up guideline for cervical cancer. Disease response and disease progression will be assessed using clinical examination. Quality of life will be estimated at baseline, at the end of neoadjuvant chemotherapy, before intracavitary brachytherapy and at each follow-up visit until 3 years after randomization.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 310
• Est. completion date: December 2026
• Est. primary completion date: September 2026
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Women with histologically proven invasive carcinoma of the uterine cervix and para aortic lymphadenopathy determined by either a positive positron emission tomography with 2-deoxy-2-[fluorine-18]fluoro- D-glucose integrated with computed tomography or if negative positron emission tomography computed tomography based on histological examination of paraaortic lymph node dissection.

• Performance status Eastern Cooperative Oncology Group 0-2

• Stage International Federation of Gynecology and Obstetrics IB1 to IVA at diagnosis with para-aortic lymph node involvement

• Adenocarcinoma or squamous cell carcinoma or adenosquamous carcinoma

• Adequate renal function (creatinine clearance =60 mL/min)

• Adequate hepatic function (bilirubin <1.5 times normal and Serum Glutamooxaloacetate Transferase < 3 times normal)

• Adequate hematopoietic function Platelet count > 100x10 9/l and Absolute neutrophil count > 1.5X10 9/l)

• Written Informed consent for participation

Exclusion Criteria:

• Stage Federation of Gynecology and Obstetrics IVB at diagnosis

• Others histologies than adenocarcinoma, squamous cell carcinoma and adenosquamous carcinoma.

• Women who receive any prior chemotherapy for her cervical cancer

• Pregnant or lactating women

• Prior ( within the last 5 years) malignancies other than non-melanoma skin cancer

• Inadequate renal, hepatic or hematopoietic function (Cf previously)

• Cardiovascular pathology New York Heart Association II or more

• Pre-existing Peripheral neuropathy Common toxicity Criteria grade = 2

Related Conditions & MeSH terms

• Cervical Cancer TNM Staging Regional Lymph Nodes (N)
• Uterine Cervical Neoplasms

Intervention

Drug:
• Carboplatin
carboplatin aera Under curve 5 on day 1, every 21 days during 3 cycles
• Paclitaxel
paclitaxel 175 mg/m² on day 1, every 21 days during 3 cycles
• Cisplatin
Cisplatin 40mg/m² given once a week during 5 weeks

Radiation:
• Radiotherapy
45 gray to the pelvis and para aortic area over 5 weeks + intracavitary brachytherapy alone or prior to surgery, depending on response to treatment according to the current guidelines

Locations

Country	Name	City	State
France	CHU de Bordeaux	Bordeaux
France	Centre Jean Perrin	Clermont-Ferrand
France	CHI Créteil	Créteil
France	Institut Paoli Calmettes	Marseille
France	CH Lyon Sud	Pierre-Bénite
France	CHU de Poitiers	Poitiers
France	Institut de Cancérologie de l'Ouest - Nantes	Saint-Herblain
France	CHU La Réunion	Saint-Pierre
France	Clinique Pasteur	Toulouse
France	University Hospital Toulouse	Toulouse
France	CHU de Tours	Tours

Sponsors (2)

Lead Sponsor	Collaborator
University Hospital, Toulouse	Institut Claudius Regaud

Country where clinical trial is conducted

France, 

References & Publications (5)

Chantalat E, Vidal F, Leguevaque P, Lepage B, Mathevet P, Deslandres M, Motton S. Cervical cancer with paraaortic involvement: do patients truly benefit from tailored chemoradiation therapy? A retrospective study on 8 French centers. Eur J Obstet Gynecol Reprod Biol. 2015 Oct;193:118-22. doi: 10.1016/j.ejogrb.2015.07.017. Epub 2015 Aug 5. — View Citation

Duenas-Gonzalez A, Zarba JJ, Patel F, Alcedo JC, Beslija S, Casanova L, Pattaranutaporn P, Hameed S, Blair JM, Barraclough H, Orlando M. Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J Clin Oncol. 2011 May 1;29(13):1678-85. doi: 10.1200/JCO.2009.25.9663. Epub 2011 Mar 28. — View Citation

Grigsby PW, Heydon K, Mutch DG, Kim RY, Eifel P. Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes. Int J Radiat Oncol Biol Phys. 2001 Nov 15;51(4):982-7. doi: 10.1016/s0360-3016(01)01723-0. — View Citation

Singh RB, Chander S, Mohanti BK, Pathy S, Kumar S, Bhatla N, Thulkar S, Vishnubhatla S, Kumar L. Neoadjuvant chemotherapy with weekly paclitaxel and carboplatin followed by chemoradiation in locally advanced cervical carcinoma: a pilot study. Gynecol Oncol. 2013 Apr;129(1):124-8. doi: 10.1016/j.ygyno.2013.01.011. Epub 2013 Jan 24. — View Citation

Varia MA, Bundy BN, Deppe G, Mannel R, Averette HE, Rose PG, Connelly P. Cervical carcinoma metastatic to para-aortic nodes: extended field radiation therapy with concomitant 5-fluorouracil and cisplatin chemotherapy: a Gynecologic Oncology Group study. Int J Radiat Oncol Biol Phys. 1998 Dec 1;42(5):1015-23. doi: 10.1016/s0360-3016(98)00267-3. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall survival	time between random assignment and death resulting from any cause	3 years
Secondary	progression free survival	time from randomization to first documentation of disease progression or death due to any cause.	fron date of randomization until the date of first documented progression or date of death from any cause, assessed up to 3 years
Secondary	adverse events	classified using the Common Terminology Criteria for Adverse Events and coded using Medical Dictionary for Regulatory Activities dictionary Pattern of disease recurrence will include locoregional recurrence and distant metastasis	3 years
Secondary	quality of life questionnaire C30 and CX24	assessed using the European Organization for Research and Treatment Quality of Life Questionnaire C30 and CX24, all subscales responses will be converted to 0 to 100 scales according to European Organization for Research and Treatment guidelines	3 years
Secondary	patterns of first relapse	location of relapse or metastasis by magnetic resonance imaging	3 years